{"id":"NCT02501928","sponsor":"Pfizer","briefTitle":"Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.","officialTitle":"LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FESOTERODINE IN JAPANESE PEDIATRIC SUBJECTS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY) WHO HAVE COMPLETED 24 WEEKS TREATMENT IN STUDY A0221047","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-05","primaryCompletion":"2020-04-01","completion":"2020-04-01","firstPosted":"2015-07-17","resultsPosted":"2020-10-26","lastUpdate":"2020-11-30"},"enrollment":12,"design":{"allocation":"NON_RANDOMIZED","model":null,"masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Urinary Bladder, Neurogenic"],"interventions":[{"type":"DRUG","name":"Fesoterodine PR 4 mg","otherNames":[]},{"type":"DRUG","name":"Fesoterodine PR 8 mg","otherNames":[]},{"type":"DRUG","name":"Fesoterodine BIC 2 mg","otherNames":[]},{"type":"DRUG","name":"Fesoterodine BIC 4 mg","otherNames":[]}],"arms":[{"label":"Fesoterodine PR 4 mg","type":"EXPERIMENTAL"},{"label":"Fesoterodine PR 8 mg","type":"EXPERIMENTAL"},{"label":"Fesoterodine BIC 2 mg","type":"EXPERIMENTAL"},{"label":"Fesoterodine BIC 4 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the safety and tolerability of fesoterodine following once daily long-term treatment in Japanese pediatric neurogenic detrusor overactivity (NDO) subjects.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Merged Data of Studies A0221047 and A0221109","timeFrame":"Up to a maximum of 56 weeks (24 weeks of treatment in A0221047 and 32 weeks [28 weeks treatment + 4 weeks follow up post last dose] in A0221109)","effectByArm":[{"arm":"Cohort 1","deltaMin":2,"sd":null},{"arm":"Cohort 2","deltaMin":9,"sd":null},{"arm":"Fesoterodine 8 mg Tablet","deltaMin":2,"sd":null},{"arm":"Fesoterodine 2 mg Capsule","deltaMin":6,"sd":null},{"arm":"Fesoterodine 4 mg Capsule","deltaMin":3,"sd":null},{"arm":"Total of Treatment Groups","deltaMin":11,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":3},"locations":{"siteCount":7,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0221109&StudyName=Long-term%20Extension%20Study%20To%20Evaluate%20The%20Safety%20Of%20Fesoterodine%20In%20Japanese%20Pediatric%20Subjects%20With%20Symptoms%20Of%20Detrusor%20Overactivity%20Associated%20With%20A%20Neurological%20Condition%20%28neurogenic%20Detrusor%20Overactivity%29%20Who%20Have%20Completed%2024%20Weeks%20Treatment%20In%20Study%20A0221047"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":2},"commonTop":["Nasopharyngitis","Asymptomatic bacteriuria","Pyrexia","Myopia","Diarrhoea"]}}